Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study.

MLA

Chatzimichail, Giannis, et al. “Drug Survival of Secukinumab, Ustekinumab, and Certolizumab Pegol in Psoriasis: A 2-Year, Monocentric, Retrospective Study.” Journal of Dermatological Treatment, vol. 33, no. 3, May 2022, pp. 1749–53. EBSCOhost, https://doi.org/10.1080/09546634.2020.1854428.

APA

Chatzimichail, G., Günther, J., Ständer, S., & Thaçi, D. (2022). Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study. Journal of Dermatological Treatment, 33(3), 1749–1753. https://doi.org/10.1080/09546634.2020.1854428

Chicago

Chatzimichail, Giannis, Julia Günther, Sascha Ständer, and Diamant Thaçi. 2022. “Drug Survival of Secukinumab, Ustekinumab, and Certolizumab Pegol in Psoriasis: A 2-Year, Monocentric, Retrospective Study.” Journal of Dermatological Treatment 33 (3): 1749–53. doi:10.1080/09546634.2020.1854428.